Original article

Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Southern Brazil

Ludmila Gonçalves Entiauspe\textsuperscript{a,b}, Fabiana Kömmling Seixas\textsuperscript{a,c}, Emily Montosa Nunes\textsuperscript{a}, Fernanda Martins Rodrigues\textsuperscript{a}, Odir A. Dellagostin\textsuperscript{a,c}, Tiago Collares\textsuperscript{a,c}, Mariângela Freitas da Silveira\textsuperscript{b,d,*}

\textsuperscript{a} Molecular and Cellular Oncology Research Group, Biotechnology Unit, Technology Development Center, Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil
\textsuperscript{b} Post-Graduate Programme in Epidemiology, Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil
\textsuperscript{c} Post-Graduate Programme in Biotechnology, CDTec, Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil
\textsuperscript{d} Maternal and Child Department, Faculty of Medicine, Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil

\textbf{ARTICLE INFO}

Article history:
Received 11 November 2013
Accepted 11 July 2014
Available online 1 September 2014

Keywords:
HPV infection
HIV infection
Cervical cancer
Epidemiology

\textbf{ABSTRACT}

Background: It is believed that Human Papillomavirus (HPV) and Human Immunodeficiency Virus coinfection contributes to increase the risk for cervical intraepithelial injuries. Several factors may contribute to cervical cancer (CC) development, including genetic variants such as TP53 and MDM2 gene polymorphisms.

Materials and methods: A hundred HIV-infected women were examined for HPV detection and its genotypes, as well as the frequencies of the SNPs Arg72Pro and SNP309 and their associations with CC risk factors. Nested Polymerase Chain Reaction (nPCR) was used for HPV detection and PCR-RFLP for TP53 and MDM2 SNP309 genotyping.

Results: HPV DNA was detected in 68% of samples. A higher frequency of low-risk HPV genotypes (66.7%) was observed when compared to high-risk genotypes (33.3%). Nine different HPV genotypes were identified, with the highest prevalence of HPV-6, followed by HPV-16 and 31. p53 Arg72Arg and SNP309 TG genotype were the most prevalent. HPV genotyping was performed by sequencing.

Conclusion: The data obtained suggest that HIV-infected women are more susceptible to be infected by low-risk HPV (LR-HPV) genotypes than by high-risk (HR-HPV), and Pro72Pro of TP53 gene and TG of MDM2 SNP309 genotypes apparently seem to be protective factors among HIV-infected women for HPV acquisition and HR-HPV infection, respectively, in a sample of Southern Brazilian woman. Future investigations in larger populations are necessary to better understand the potential roles of these SNPs and the behavior of non-oncogenic HPV genotypes in HIV-mediated immunosuppression cases.

© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND

* Corresponding author at: Centro de Pesquisas Epidemiológicas, Rua Marechal Deodoro, 1160 – 3º Piso, Bairro Centro, Cep: 96020-220, Caixa Postal 464, Pelotas City, RS, Brazil.
E-mail address: maris.sul@terra.com.br (M.F. da Silveira).
http://dx.doi.org/10.1016/j.bjid.2014.07.005
1413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
Introduction

It is estimated that cervical cancer (CC) is the second most common type of cancer in the Brazilian female population and the third cause of death in women.1 Today, it is possible to confirm that CC development is closely associated with the Human Papillomavirus (HPV) presence and persistence;2 with HPV DNA detected in up to 99.7% of invasive CC cases across the world.3 The World Health Organization attributes to cervical infection with HPV-16 or -18 about 70% of invasive CC cases in Brazil.4 Cervical intraepithelial neoplasia (CIN) development and cervical cancer in HPV-infected women are associated with risk factors, such as young age, high number of sexual partners throughout life, early sexual debut, smoking, genetics variants, among others.5,6 Moreover, co-infections, such as those with Human Immunodeficiency Virus (HIV) and Chlamydia trachomatis bacterium, may be involved as co-factors to CC development, acting as adjuvants of the neoplastic process.7,8

The polymorphism on codon 72 (Arg72Pro) of TP53 tumor suppressor gene has been extensively investigated regarding association with a wide range of cancers worldwide. In HPV-infected cells, the E6 oncoprotein binds to p53 protein and promotes its degradation through an ubiquitin proteolytic system altering the p53 activity in some processes, such as tumorigenesis, transcription regulation, telomerase activation, and apoptosis, thus resulting in deregulation of the cell cycle.9 Previous studies have shown that the Arg72Arg genotype is related to a higher risk for CC development when compared to the Pro72Pro genotype.10

Studies have shown that a Single Nucleotide Polymorphism (SNP) on promoter region of MDM2 gene, the SNP309 (T to G change on nucleotide 309 of the first intron), results in a higher level of MDM2 mRNA and MDM2 protein, and consequent reduction of the p53 pathway.11 The SNP309 occurs at a relatively high frequency in the general population, and it was shown that it presents a strong association with HPV-mediated cervical carcinogenesis.12

Based on the presented data, this study aimed to investigate the HPV infection spectrum, to identify the most prevalent genotypes, to determine the frequencies of SNPs Arg72Pro and MDM2 SNP309, and their association with possible risk factors for viral persistence and for the development of pre-neoplastic and neoplastic lesions of the uterine cervix in HIV-infected women. The study was conducted in patients of the Service of Specialized Care for HIV/AIDS, College of Medicine, Federal University of Pelotas (Serviço de Assistência Especializada em HIV/SIDA – SAE-UFPel).

Materials and methods

Study type, characterization and sample size

This was a cross-sectional study consisting of 100 HIV-infected women, which were sequentially randomly invited to participate. The eligibility criteria were: not being in the menstrual period, aged between 18 and 45 years, and not being pregnant. Women who had undergone cervical conization and/or hysterectomy were excluded. The Epi-Info 6.0 software was used to calculate the required sample size for the prevalence study, using an estimated HPV prevalence of 80%, with a 95% confidence level and 80% testing power.

Logistics

All participants completed a standardized questionnaire with the purpose of obtaining information about the patient and other relevant epidemiological and socio-demographic variables. An adapted questionnaire from an intervention study with HIV-infected (HIV+) women conducted at SAE-UFPel was used.13 The Research Ethics Committee of the College of Medicine of the Federal University of Pelotas approved the present study by June 2009, and informed consent was obtained from all participants. All procedures were conducted according to the Helsinki Declaration guidelines.

Sample collection and DNA extraction

Cytobrushes were collected containing cervical secretion samples from the endocervical region. The collected samples were stored in eppendorf tubes containing 300 μL of Cellular Lysis Solution (PUREGENETM Gentra Systems Kit) and routed in an appropriated container to the Laboratory of Functional Genomics (Center for Technology Development – CDTeC-UFPel) for viral molecular detection by Polymerase Chain Reaction (PCR). Before DNA extraction, the samples were subjected to enzymatic digestion with 1.5 μL of Proteinase K (10 mg/mL) and incubated for 16 h at room temperature. The extracted DNA was performed according to manufacturer’s specifications (PUREGENETM Gentra Systems Kit).

TP53 gene polymorphism analysis

The Arg72Pro polymorphism of TP53 gene was analyzed by PCR using the 72A and 72S primers described by Lin et al.14 The amplification conditions consisted of an initial denaturation at 94 °C for 3 min followed by 40 cycles at 94 °C for 30 s, 57 °C for 30 s, 72 °C for 30 s, and a final extension at 72 °C for 3 min.

The PCR product obtained was subjected to enzymatic digestion by RFLP (Restriction Fragment Length Polymorphism) using the Bst UI restriction enzyme for restriction fragments analysis. The fragments obtained were analyzed by agarose gel electrophoresis (2% agarose in TBE buffer), stained with GelRedTM (Biotium Inc., CA) and observed under ultraviolet light (UV). The p53 genotypes were characterized according to Lin et al.14

MDM2 SNP309 analysis

The MDM2 T/G SNP309 polymorphism was analyzed by PCR using the primers described by Sotomaa et al.15 The reaction was performed with initial denaturing at 94 °C for 10 min followed by 30 subsequent cycles at 94 °C for 30 s, 60 °C for 1 min, 72 °C for 1 min, and a final extension at 72 °C for 10 min. The PCR products were analyzed by agarose gel electrophoresis (2%
agarose gel in TBE buffer), stained with GelRed™ (Biотium Inc., CA) and observed under UV. The genotyping was performed by RFLP using the MspAI restriction enzyme.15

**HPV DNA detection by PCR**

The HPV DNA detection was performed by the nested PCR (nPCR) technique, which is performed in two stages. The first stage used a pair of external primers (MY09/11) previously described by Manos et al.16 and the second stage used a pair of internal primers (GPS/6) described by Snijders et al.17 Both reactions were performed with initial denaturation at 95 °C during 9 min and final extension at 72 °C for 5 min.18,19 The reaction conditions for the first stage consisted of 40 subsequent cycles of 94 °C during 30 s for denaturation, 45 °C during 30 s for annealing, and 72 °C for 30 s for extension. For the second stage were used 40 subsequent cycles of 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 1 min for denaturation, annealing and extension, respectively.19 The PCR products obtained were subjected to agarose gel electrophoresis (1.0% and 2.0% agarose for the first and second rounds, respectively) and observed under UV. A reaction positive control (RPC) consisting of 450pb corresponding to HeLa cells (HPV-16) and a negative control (NC) without any DNA were used.

**Sequencing of the PCR products**

The HPV DNA-positive samples were sequenced for identification of the present genotypes. The products obtained from nPCR were purified using the Illuma™ GFX™ PCR DNA and Gel Band Purification Kit (GE Health Care) and sequenced on a MegaBACE 500 (GE Healthcare).

**Sequence analyses**

Forward and reverse sequences were aligned and a consensus sequence was obtained for each case using VECTOR NTI® 10.0 software. The genotypes were determined comparing the consensus sequence with reference sequences deposited in DNA databases through the nucleotide Basic Local Search Tool (BLASTn). For the samples edition and alignment, the VECTOR NTI® 10.0 software was used.

**Data analyze**

Data was entered by two different data clerks with the software Epi-Info® Windows version in order to make a further comparison and, thus, ensure better data quality. An automatic data checking was performed at the time of typing using the Epi-Info® Check function for consistency and amplitude checking. To identify and correct coding, proofreading and typing inconsistencies, a data cleaning was performed by obtaining frequencies of the collected variables. The analysis was performed using the SPSS® v16.0 software. Chi-square tests ($\chi^2$) were used for the univariate analyses. Multivariate logistic regression analysis was also performed. Variables remained at the model if their level of significance was below 0.20, as potential confounders for the next level. A p-value < 0.05 was considered statistically significant.

**Results**

Most participants were aged between 40 and 45 years (53%), were white (51%), 45.3% had between five and eight years of education, were married or in a stable relationship (64.4%), and the overriding majority had per capita income of one minimum wage (96.6%). Regarding behavioral variables, 59.6% were non-smokers, 60% reported not having consumed alcohol in the last four weeks, 63.3% reported having used a condom at last sexual intercourse, 56% were aged between 12 and 15 years at sexual debut, 40.8% had more than nine sexual partners throughout life, and over 90% reported never had exchanged sex for money and/or drugs.

The TP53 genotyping showed that, out of the 100 samples analyzed, 43% presented Arg72Pro genotype, 39% were Arg72Arg and 18% were Pro72Pro. The alleles frequency showed 82% for the A (AA + AP) allele and 61% for the P (AP + PP) allele. The MDM2 SNP309 genotyping showed a higher frequency for the TG genotype (45%). Moreover, the T (TT + TG) allele was the most frequent (84%) compared to the C (GG + TG) allele (61%).

HPV infection was observed in 68% of the samples. Nine different HPV genotypes were found, with a higher prevalence of HPV-6, followed by HPV-16, HPV-31, HPV-11, HPV-18, HPV-35, HPV-45, HPV-56 and HPV-81. Eleven samples could not be genotyped by sequencing, and these were categorized as HPV-X. According to the epidemiologic classification of HPV types associated with cervical cancer, 33.3% of the samples were high-risk oncogenic HPV (HR-HPV) and 66.7% were low-risk oncogenic HPV (LR-HPV).20

Table 1 shows the univariate analysis, having HPV infection as outcome related to socioeconomic, demographic and behavioral variables. There was no statistically significant association with any of the variables. Table 2 shows the frequency distribution of genotypes and alleles of Arg72Pro and MDM2 SNP309. The Arg72Arg genotype of the TP53 gene was the most prevalent among the HPV+ group (45.6%), predominating A (AA + AP) allele (82.4%) compared to P (AP + PP) allele (54.4%). The MDM2 SNP309 presented the TG genotype as the most prevalent (50%), as well as the T (TT + TG) allele (83.8%) when compared to the G (GG + TG) allele (66.2%). The LR-HPV infected group showed frequencies similar to those shown by the HR-HPV infected group, except for some variables. Regarding the TP53 gene polymorphism, it was observed that 52.6% of the HR-HPV infected samples and 47.4% of the LR-HPV infected samples presented the Arg72Arg genotype. In addition, the A (AA + AP) allele was more frequent in both infections (LR and HR) when compared to the P (AP + PP) allele ($p < 0.05$). Furthermore, the MDM2 SNP309 genotyping showed a higher frequency of TT genotype (42.1%) in the HR-HPV group, as well as higher frequency of TG genotype (65.8%) in the LR-HPV group ($p < 0.05$). The T (TT + TG) allele was more frequent when compared to the G (GG + TG) allele in both groups.

The multivariate analyses showed no statistically significant differences and their results are not reported here.
Table 1 – Interaction of HPV infection and the oncogenic potential risk on the variables of HIV-positive women.

| Variables                        | HPV infection |          |          |          |          |          |          |
|----------------------------------|---------------|----------|----------|----------|----------|----------|----------|
|                                  | Positive (%)  | Negative | RR (IC 95%) |          |          |          |          |
| Age (years)                      |               |          |          |          |          |          |          |
| 18–24                            | 2.9           | 3.1      | 0.71 (0.06–8.54) |          |          |          |          |
| 25–30                            | 5.9           | 18.8     | 0.23 (0.05–0.97) |          |          |          |          |
| 31–35                            | 17.6          | 15.6     | 0.86 (0.25–2.88) |          |          |          |          |
| 36–39                            | 16.2          | 18.8     | 0.65 (0.20–2.11) |          |          |          |          |
| 40–45                            | 57.4          | 43.8     | 1         |          |          |          |          |
| p = 0.342                        |               |          |          |          |          |          |          |
| Skin color                       |               |          |          |          |          |          |          |
| White                            | 55.9          | 40.6     | 2.02 (0.82–4.99) |          |          |          |          |
| Non-white                        | 44.1          | 59.4     | 1         |          |          |          |          |
| p = 0.155                        |               |          |          |          |          |          |          |
| Schooling (years)                |               |          |          |          |          |          |          |
| >5                               | 23.1          | 13.3     | 2.43 (0.66–8.99) |          |          |          |          |
| 5–8                              | 46.2          | 43.3     | 1.50 (0.57–3.89) |          |          |          |          |
| >8                               | 30.8          | 43.3     | 1         |          |          |          |          |
| p = 0.378                        |               |          |          |          |          |          |          |
| Marital status                   |               |          |          |          |          |          |          |
| Married/consensual union         | 63.2          | 68.8     | 1         |          |          |          |          |
| Single                           | 22.1          | 18.8     | 0.99 (0.26–3.78) |          |          |          |          |
| Separated/divorced/widowed       | 14.7          | 12.5     | 1.35 (0.27–6.67) |          |          |          |          |
| p = 0.865                        |               |          |          |          |          |          |          |
| Per capita income (minimum wages)|               |          |          |          |          |          |          |
| 0–1                              | 96.5          | 96.8     | 0.91 (0.80–10.53) |          |          |          |          |
| 2                                | 3.5           | 3.2      | 1         |          |          |          |          |
| p = 0.944                        |               |          |          |          |          |          |          |
| Family income (minimum wages)    |               |          |          |          |          |          |          |
| Up to 1                          | 29.8          | 32.3     | 0.18 (0.02–1.72) |          |          |          |          |
| Up to 2                          | 33.3          | 45.2     | 0.15 (0.01–1.33) |          |          |          |          |
| Up to 3                          | 21.1          | 19.4     | 0.22 (0.02–2.18) |          |          |          |          |
| Over 4                           | 15.8          | 3.2      | 1         |          |          |          |          |
| p = 0.307                        |               |          |          |          |          |          |          |
| Cigarette smoking                |               |          |          |          |          |          |          |
| Current smoker                   | 41.2          | 38.7     | 0.90 (0.37–2.15) |          |          |          |          |
| No-smoker                        | 58.8          | 61.3     | 1         |          |          |          |          |
| p = 0.817                        |               |          |          |          |          |          |          |
| Alcohol consume (last 4 weeks)   |               |          |          |          |          |          |          |
| At least once a week             | 17.6          | 25.0     | 0.75 (0.26–2.12) |          |          |          |          |
| Less than once a week            | 23.5          | 12.5     | 2.00 (0.59–6.77) |          |          |          |          |
| Never                            | 58.8          | 62.5     | 1         |          |          |          |          |
| p = 0.375                        |               |          |          |          |          |          |          |
| Use of condom (last sexual activity) | 62.7          | 65.6     | 1         |          |          |          |          |
| Yes                              | 37.3          | 34.4     | 0.88 (0.36–2.12) |          |          |          |          |
| p = 0.776                        |               |          |          |          |          |          |          |
| Sexual activity began (years)    |               |          |          |          |          |          |          |
| <15                              | 51.5          | 65.6     | 1.71 (0.47–6.19) |          |          |          |          |
| 16–18                            | 38.2          | 15.6     | 5.19 (1.16–23.17) |          |          |          |          |
| ≥19                              | 10.3          | 18.8     | 1         |          |          |          |          |
| p = 0.062                        |               |          |          |          |          |          |          |
| Sexual partners (in life)        |               |          |          |          |          |          |          |
| Up to 1                          | 3.0           | 3.1      | 1         |          |          |          |          |
| 2–4                              | 39.4          | 25.0     | 1.07 (0.90–12.94) |          |          |          |          |
| 5–8                              | 18.2          | 28.1     | 1.75 (0.62–4.87) |          |          |          |          |
| ≥9                               | 39.4          | 43.8     | 0.71 (0.24–2.11) |          |          |          |          |
| p = 0.497                        |               |          |          |          |          |          |          |
Table 1 (Continued)

| Variables                                          | HPV infection       | RR (IC 95%)        |
|----------------------------------------------------|---------------------|-------------------|
|                                                    | Positive (%)        | Negative (%)      |                   |
| Gave/received drugs and/or money for sex           | 80.0                | 20.0              | 1.93 (0.20–18.07) |
| Yes                                                | 67.4                | 32.6              | 1                 |
| No                                                 | p = 0.555           |                   |                   |
| Last Pap test                                       | 8.6                 | 13.3              | 0.25 (0.03–1.86)  |
| Never                                              | 70.7                | 29.3              | 1                 |
| <3 years                                           | 20.7                | 13.3              | 0.35 (0.07–1.76)  |
| >3 years                                           | 6.2                 | 93.8              | 0.80 (0.11–5.77)  |
| Do not remember                                    | p = 0.336           |                   |                   |
| Visual inspection with acetic acid (VIA)           | 10.4                | 6.7               | 1.63 (0.31–8.37)  |
| Positive                                           | 89.6                | 93.3              | 1                 |
| Negative                                           | p = 0.553           |                   |                   |
| Visual inspection with Lugol’s iodine (VILI)       | 10.4                | 6.7               | 1.63 (0.31–8.37)  |
| Positive                                           | 89.6                | 93.3              | 1                 |
| Negative                                           | p = 0.553           |                   |                   |
| Pap test results                                    | Normal              | 60.7              | 1                 |
| Positive                                           | 65.5                | 65.5              | 1                 |
| Negative                                           | 31.1                | 27.6              | 0.77 (0.13–4.39)  |
| Altered                                            | 8.2                 | 6.9               | 0.95 (0.15–5.95)  |
| p = 0.905                                          |                     |                   |                   |
| CD4 counting cells (cells/mm$^3$)                   | <350                | 25.4              | 0.73 (0.25–2.10)  |
| Positive                                           | 20.0                | 20.0              | 1                 |
| Negative                                           | p = 0.565           |                   |                   |
| >350                                               | 76.3                | 76.3              | 1                 |

Table 2 – Interaction of Arg72Pro and MDM2 SNP309 on the HPV infection and oncogenic risk status.

| HPV infection | p     | HPV genotypes | p     |
|---------------|-------|---------------|-------|
|               | HPV-positiven (%) | HPV-negativen (%) | High-risk (%) | Low-risk (%) |
| P53 genotypes |       |               |       |             |
| Arg72Arg      | 31 (45.6) | 8 (25)         | 10 (52.6) | 18 (47.4) |
| Arg72Pro      | 25 (36.8) | 18 (56.2)      | 6 (31.6) | 14 (36.8) |
| Pro72Pro      | 12 (17.6) | 6 (18.8)       | 3 (15.8) | 6 (15.8)  |
| P53 alleles   |       |               |       |             |
| Arginine carriers | 56 (84.2) | 26 (81.2)      | 16 (84.2) | 32 (84.2) |
| Proline carriers | 37 (554.4) | 24 (75)       | 9 (47.4) | 20 (52.6) |
| MDM2 genotypes |       |               |       |             |
| TT            | 23 (33.8) | 16 (50)       | 8 (42.1) | 9 (23.7)  |
| TG            | 34 (50)   | 11 (34.4)      | 6 (31.6) | 25 (65.8) |
| GG            | 11 (16.2) | 5 (16.2)       | 5 (26.3) | 4 (10.5)  |
| MDM2 alleles  |       |               |       |             |
| Thymine carriers | 57 (83.8) | 27 (84.4)      | 14 (73.7) | 34 (89.5) |
| Guanine carriers | 45 (66.2) | 16 (50)       | 11 (57.9) | 29 (76.3) |

* Total of 57 samples.

Discussion

Studies have shown that HPV infection is most common in HIV-infected women and it is believed that HIV contributes to increase HPV viral load and hence its persistence, increasing the risk for cervical intraepithelial lesions. The HPV infection prevalence in this study was 68%. These observations are consistent with a meta-analysis study reported by Clifford et al., who observed higher HPV prevalence in HIV-infected women in Brazil and Mexico (57.3%) compared to the global prevalence (36.5%).

In this study women older than 40 years, with low income, early sexual debut and high number of sexual partners throughout life showed greater risk to acquire HPV infection.
Sauvaget et al. in a study conducted with women with average age of 39 years from rural areas of India, found an association with low income, early age at first pregnancy, and low educational level. They suggested that constant increase in HPV prevalence in middle-aged women may result from reduced ability of the host to eliminate HPV infection, nutritional deficiencies, or from the virus ability to become latent and be reactivated due to a failure of immune surveillance or hormonal factors associated to older age. Moreover, the HR-HPV prevalence usually shows a constant decline with the increasing age seen in high-income countries, in contrast to the U-shaped curves reported in some Latin-American countries. Here, an increased prevalence of HPV infection in the age group of 35–44 years old has been reported in a cross-sectional study performed in eleven countries with different cervical cancer incidences.

The genotyping by sequencing showed the presence of nine different HPV genotypes, with a higher prevalence for HPV-6, followed by HPV-16 and -31 in this study. Although most studies show that HPV-16 genotype is the most prevalent worldwide, this data is in line the report by Corrêa et al., who observed a prevalence of 63.5% of HPV-6 genotype followed by HPV-16 genotype as the second most prevalent (48.5%). Levi et al. observed similar data, with higher prevalence of HPV-6 genotype in HIV-infected women (87%). McKenzie et al., in a meta-analysis study, observed that different geographic areas, such as Zambia, Brazil and Rochester (New York, United States), show different HR-HPV infections by less prevalent genotypes when compared to the population in general. Furthermore, they show that cervical malignancy has a different behavior in HIV-infected patients, as well as benign manifestations of HPV.

Apparently, the HIV infection exerts a multifactorial oncogenic function in cervical cancer development, interfering in the immune function and also in the direct promotion of the lesion development. The HIV-1 Tat protein seems to promote the cellular proliferation and positively regulate the E6 and E7 HPV genes, responsible for the malignant cellular transformation. Recent data indicate that significant changes occur in the uterine cervix in HPV/HIV co-infected women suggesting that the immune response appears to be negatively regulated, except for the RANTES protein (Regulated on Activation, Normal T cell Expressed and Secreted), which has been found to be increased. RANTES levels were found significantly increased in plasma and tissue from patients with breast cancer and cervical cancer, suggesting that positive regulation of RANTES and other changes in cervical tissue associated with HPV/HIV co-infection (such as those mediated by HIV-1 Tat protein) would permit less aggressive HPV genotypes to cause malignant transformation. Some authors suggest that this variation of genotypes is due to socioeconomic and behavioral characteristics, which may be different in HIV-infected women, besides the geographic region where the research is conducted. With regard to HPV infection stratified by genotype, further studies comparing innate immunity between HIV+ and HIV− women are necessary. These studies will help to individualize treatment and prevention in the group of women at increased risk of morbidity and mortality due to HPV-related diseases.

The ability of the persistent HPV infection to cause malignant transformation is associated to the viral DNA integration into the genome of the host. However, some studies have challenged this statement. These studies indicate that the necessity of integration for the carcinogenesis varies with the HPV genotype (for example, only 50% of the HPV-16 genome integrates with the host, while HPV-18 needs to integrate 94%). This distinction is particularly important for the comprehension of the disease etiology in HIV-infected patients, since these are commonly infected by HPV genotypes that require integration with the host genome for the carcinogenesis development. Furthermore, recent studies have described the association between the integration rate and the cervical dysplasia severity.

Concerning the Arg72Pro TP53 gene polymorphism, the present study found no statistically significant relation between observed genotypes, frequency of the Arg and Pro alleles and HPV presence. Moreover, it is worth noting that the controversial results regarding the association between TP53 gene polymorphism and cervical cancer can occur due to some factors, such as differences in the TP53 polymorphism among ethnic groups, sample size, choice of the control to be used and DNA obtaining source. For example, a study using normal cervical samples and high- and low-risk lesion samples failed to show an association between the presence of the polymorphism and frequency of the Arg and Pro alleles with increased risk for CC, suggesting that the association between the TP53 gene polymorphism and the development of HPV-associated cervical neoplasia is improbable. However, in a meta-analysis study performed one year later, it was observed significantly higher odds of progression from SIL to CC with the p53 Arg allele [OR 1.37; 95% CI, 1.15–1.62; p < 0.001] in HPV-positive individuals.

There are a few studies correlating MDM2 SNP309 to CC susceptibility, although SNP309 presents a relatively high frequency in the general population and its presence has been associated with the acceleration of tumorigenesis and time of tumor onset. In this study, TT and TG genotypes were significantly more frequent in HR-HPV and LR-HPV groups, respectively, but presence or frequency of the T and G alleles was not significantly associated with HPV infection. There is an inconsistency regarding the role of MDM2 SNP309 in susceptibility to the CC development. Nunobi et al. found a prevalence of 78.8% for the TG genotype among high-grade squamous intraepithelial lesion (HSIL) samples when compared with low-grade squamous intraepithelial lesion (LSIL) samples and controls, among HR-HPV positive samples and, specially, the HPV-16 and -18 genotypes. However, there was no association between the samples and the frequencies of T and G alleles. Meissner et al. in a study conducted in northeastern Brazil for identification of the MDM2 SNP309 in 72 CC samples and 100 normal samples by PCR found no statistically significant association between the SNP309 and the risk and early diagnosis for CC. Also, no difference was observed for the frequency of alleles or genotypes among the group of patients diagnosed with CC at an early age (below 40 years) and the group of older patients. On the other hand, Arvanitis and Spandonios through the analysis of mRNA expression profiles of 24 G1- and S-phase checkpoint genes in 35 cervical carcinomas samples, 26 HSIL samples, 33 LSIL samples, and
28 normal cervical samples (used as controls), showed that the MDM2 was found positively regulated in SIL, suggesting that MDM2 gene is a potential candidate for cervical neoplasia development.\textsuperscript{10} Although this data suggest that HR-HPV infection and the MDM2 SNP309 may be associated with cervical carcinogenesis, in our study there were no samples from patients with CC, which can be considered a limiting factor for these two associations types, since the polymorphisms of both MDM2 and TP53 genes are associated with increased risk for CC and not with susceptibility to HPV infection.

A better understanding of the HPV infection evolution in these women, the viral persistence occurrence, and possible factors associated to the malignant cervical lesions development are necessary for establishing more appropriate CC screening routines in this population. This is essential for the proposition of more appropriate monitoring strategies and treatment according to the Brazilian health service reality, as well as patients.

**Conclusion**

Current recommendations are partly based on the knowledge of professionals about CC management and HIV infection in women. The data obtained in this study suggest that HIV-infected women are more susceptible to be infected by the LR-HPV genotypes than by the high-risk HR-HPV. Additionally, Pro72Pro of TP53 gene and TG of MDM2 SNP309 genotypes apparently seem to be protective factors among HI-infected women for HPV acquisition and HR-HPV infection, respectively, in a sample of Southern Brazilian woman. Moreover, further studies are necessary for the investigation of the behavior of low-risk genotypes infecting HIV-mediated immunosuppressed cases.

**Conflicts of interest**

The authors declare no conflicts of interest.

**Acknowledgements**

The authors are grateful to Brazilian National Research Council (CNPq).

**References**

1. Ministério da Saúde do Brasil – Instituto Nacional do Câncer (INCA). Estimativas 2014. Rio de Janeiro: Incidência de Câncer no Brasil; 2013.
2. Chen AA, Heideman AM, Boon D, et al. Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology. 2014;448:356–62.
3. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. Can Med Assoc J. 2003;168:421–5.
4. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in Brazil. Health Ministry Press; 2014.
5. Rocha-Brischili SC, Gimenes F, de Abreu AL, et al. Risk factors for cervical HPV infection and genotypes distribution in HIV-infected South Brazilian woman. Infect Agents Cancer. 2014;9:6.
6. Wang SS, Gonzalez P, Yu K, et al. Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS ONE. 2010;5:e8667.
7. Tavares MCM, de Macêdo JL, de Lima Jr SF, et al. Chlamydia trachomatis infection and human papillomavirus in women with cervical neoplasia in Pernambuco-Brazil. Mol Biol Rep. 2014;41:865–74.
8. Luque AE, Jabeen M, Messing S, et al. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-Infected Women in Rochester, New York. J Infect Dis. 2006;194:428–34.
9. De Lima JL, Serafim PVP, Da Silva IDCG, Forones NM. Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer. Arq Gastroenterol. 2006;43:8–13.
10. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–34.
11. Wan Y, Wu W, Yin Z, Guan P, Zhou B. MDM2 SNP309, gene–gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 2011;11:208.
12. NunoBiki G, Ueda M, Yamamato M, et al. Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathol Res Int. 2011;2011:8.
13. Silveira MF, Santos IS. Impact of an educational intervention to promote condom use among the male partners of HIV positive women. J Eval Clin Pract. 2006;12:102–11.
14. Lin YC, Huang HI, Wang LH, et al. Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008;44:798–804.
15. Sotamaa K, Liyanarachchi S, Mecklin JP, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res. 2005;11:6840–4.
16. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells. 1989;7:209–14.
17. Snijders PJF, Van Den Brule AJC, Schijnemakers HFJ, Snow G, Meijer CJLM, Walboomers JMM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol. 1990;71:173–81.
18. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357–61.
19. Husnjak K, Grce M, Magdic L, Pavecic K. Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. J Virol Methods. 2000;88:125–34.
20. Muñoz N, Bosch FX, Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:56–66.
21. Clifford GM, Gonçalves MAC, Franceschini S. Human papillomavirus types among women infected with HIV: a meta-analysis for the HPV and HIV Study Group. AIDS. 2006;20:2337–44.
22. Sauvaget S, Nene BM, Kelkar R, Malvi SG, Shastri SS, Sankaranarayanan R. Prevalence and determinants of high-risk human papillomavirus infection in middle-aged Indian woman. Sex Transm Dis. 2011;28:902–6.
23. Franceschi S, Herrera R, Clifford GM, et al., IARC HPV Prevalence Surveys Study Group. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677–84.
24. Corrêa CM, Teixeira NCP, de Araújo ANL, et al. Prevalence and multiplicity of HPV in HIV women in Minais Gerais, Brazil. Rev Assoc Med Bras. 2011;57:425–30.

25. Levi JE, Fernandes S, Tateno AF, et al. Presence of multiple human papillomavirus types in cervical samples from HIV-infected women. Gynecol Oncol. 2004;92:225–31.

26. McKenzie ND, Kobetz EN, Hnatyszyn J, Twiggs LB, Lucci JA. Women with HIV are commonly infected with non-16 and -18 high-risk HPV types. Gynecol Oncol. 2010;116:572–7.

27. Buonaguro FM, Tornesello ML, Buonauguro L, Delgaudio E, Beta-Giraldo E, Giraldo G. Role of HIV as cofactor in HPV oncogenesis: in vitro evidence of virus interactions. Antibiott Chemother. 1994;46:102–9.

28. Nyagol J, Leucci E, Onnis A, DeFalco G, Tigli C, Sanseverino F. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther. 2006;5:684–90.

29. Nicol AF, Nuovo GJ, Salomão-Estevez A, et al. Immune factors involved in the cervical immune response in the HIV/HPV co-infection. J Clin Pathol. 2008;61:84–8.

30. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001;7:285–9.

31. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91:226–36.

32. Cullen AF, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasms. J Virol. 1991;65:606–12.

33. Hudelist G, Manavi M, Pischinger KI, et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol. 2004;92:873–80.

34. Wanram S, Limpaiboon T, Leelayuwat C, et al. The use of viral load as a surrogate marker in predicting disease progression for patients with early invasive cervical cancer with integrated human papillomavirus type 16. Am J Obstet Gynecol. 2009;201, 79–e1.

35. Hu X, Zhang Z, Ma D, et al. TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:755–61.

36. Habbous S, Pang V, Eng L, et al. p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012;18:6407–15.

37. Meissner RV, Barbosa RN, Fernandes JV, Galvão TM, Galvão AF, Oliveira GH. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev. 2007;31:371–4.

38. Arvanitis DA, Spanidou D. Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study. Oncol Rep. 2008;20:751–60.